aTyr Pharma (NASDAQ:LIFE) Upgraded to “Buy” at Zacks Investment Research


Share on StockTwits

aTyr Pharma (NASDAQ:LIFE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Zacks.com reports. The brokerage currently has a $4.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 14.21% from the company’s current price.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

Separately, Oppenheimer restated a “buy” rating on shares of aTyr Pharma in a report on Tuesday, September 22nd. Five analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $10.13.

Shares of NASDAQ:LIFE traded down $0.16 during midday trading on Wednesday, hitting $3.94. 164,484 shares of the stock were exchanged, compared to its average volume of 649,951. aTyr Pharma has a 52-week low of $2.13 and a 52-week high of $7.27. The business’s fifty day simple moving average is $4.11 and its two-hundred day simple moving average is $3.89. The company has a market capitalization of $40.13 million, a PE ratio of -1.48 and a beta of 2.14.

aTyr Pharma (NASDAQ:LIFE) last posted its earnings results on Tuesday, November 17th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.06. aTyr Pharma had a negative return on equity of 52.75% and a negative net margin of 202.02%. The company had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.16 million. On average, analysts anticipate that aTyr Pharma will post -2.14 EPS for the current fiscal year.

Several large investors have recently modified their holdings of LIFE. Two Sigma Advisers LP grew its position in shares of aTyr Pharma by 122.7% in the second quarter. Two Sigma Advisers LP now owns 80,950 shares of the biotechnology company’s stock valued at $359,000 after purchasing an additional 44,600 shares during the last quarter. Ardsley Advisory Partners LP purchased a new position in aTyr Pharma in the third quarter worth $65,000. Acadian Asset Management LLC boosted its position in aTyr Pharma by 22.2% in the third quarter. Acadian Asset Management LLC now owns 83,052 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 15,088 shares during the last quarter. Finally, BlackRock Inc. boosted its position in aTyr Pharma by 23.8% in the third quarter. BlackRock Inc. now owns 41,411 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 7,948 shares during the last quarter. 56.03% of the stock is currently owned by institutional investors.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial.

Featured Article: Understanding Relative Strength Index

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.